Objective-We previously demonstrated that subjects with functional ATP-binding cassette (ABC) A1 mutations have increased atherosclerosis, which has been attributed to the role of ABCA1 in reverse cholesterol transport. More recently, a proinflammatory effect of Abca1 deficiency was shown in mice, potentially contributing to atherogenesis. In this study, we investigated whether ABCA1 deficiency was associated with proinflammatory changes in humans. Approach and Results-Thirty-one heterozygous, 5 homozygous ABCA1 mutation carriers, and 21 matched controls were studied. 18 Fluorodeoxyglucose positron emission tomography with computed tomographic scanning was performed in a subset of carriers and controls to assess arterial wall inflammation (target:background ratio). Heterozygous ABCA1 mutation carriers had a 20% higher target:background ratio than in controls (target:background ratio; P=0.008). In carriers using statins (n=7), target:background ratio was 21% reduced than in nonstatin users (n=7; P=0.03). We then measured plasma cytokine levels. Tumor necrosis factor α, monocyte chemoattractant protein-1, and interleukin-6 levels were increased in heterozygous and homozygous ABCA1 mutation carriers. We isolated monocytes from carriers and controls and measured inflammatory gene expression. Only TNFα mRNA was increased in monocytes from heterozygous ABCA1 mutation carriers. Additional studies in THP-1 macrophages showed that both ABCA1 deficiency and lipoproteindeficient plasma from ABCA1 mutation carriers increased inflammatory gene expression. Conclusions-Our data suggest a proinflammatory state in ABCA1 mutation carriers as reflected by an increased positron emission tomography-MRI signal in nonstatin using subjects, and increased circulating cytokines. The increased inflammation in ABCA1 mutation carriers seems to be attenuated by statins. (Arterioscler Thromb Vasc Biol.
H igh-density lipoprotein cholesterol (HDL-C) levels are inversely correlated with cardiovascular risk. [1] [2] [3] The atheroprotective effects of HDL have traditionally been attributed to its role in reverse cholesterol transport. The ATP-binding cassette transporter A1 (ABCA1) plays a crucial role in mediating cholesterol efflux from peripheral cells, including arterial wall macrophages, to lipid-poor apolipoprotein AI or preβ HDL particles. 4, 5 Homozygous ABCA1 mutation carriers display near absent HDL-C levels, whereas heterozygous carriers are characterized by half-normal HDL-C. Single nucleotide polymorphisms in the ABCA1 gene have variously been reported to have no impact on cardiovascular disease, 6, 7 or to be associated with an increased cardiovascular disease risk. 8, 9 However, studies in ABCA1 mutation carriers, displaying marked defects in cholesterol efflux and profound decreases in HDL levels, showed increased arterial wall thickness, 10, 11 and cardiovascular disease risk 8, 9 in carriers than in controls.
See accompanying editorial on page 1551
The paradigm that a macrophage-dominated inflammatory process, initiated by the deposition of cholesterol-rich lipoproteins in the arterial wall, is central to atherosclerosis has been widely accepted. 12 The molecular mechanisms linking defective cholesterol homeostasis to increased inflammation are not well understood. Recent studies have implicated defective cellular cholesterol efflux pathways in increased inflammatory gene expression in monocytes and macrophages, as well as the increased production of inflammatory cells such as monocytes and neutrophils. 13, 14 Deficiency of ABCA1 and/or ABCG1 is associated with a proinflammatory phenotype in mouse peritoneal macrophages, as well as in the macrophages of atherosclerotic plaques. [13] [14] [15] [16] Whether ABCA1 deficiency in humans represents a proinflammatory state is presently unknown.
In this study, we assessed whether ABCA1 mutation carriers exhibit proinflammatory changes in the arterial wall as measured by 18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography with computed tomography (PET/CT). We also measured plasma cytokine levels and assessed inflammatory gene expression in ABCA1-deficient monocytes/macrophages in vitro.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. 17
Results

Baseline Characteristics
Baseline characteristics of study participants are listed in the Table. Thirty-six ABCA1 mutation carriers from 14 separate families were included, comprising 3 homozygous, 2 compound heterozygous, and 31 heterozygous patients. Homozygous and compound heterozygous subjects had Tangier Disease. Subjects were carriers of the following mutations: p.Leu1056Pro, c.3535+1G>C, c.6401+2T>C, p.Asn1800his, p.Ser930Phe, p.Phe1760Valfs*21, p.Ser824Leu, p.Gln1038Ter, p.Thr929Ile, p.Arg587Trp, p.Asn935Ser, and p.Arg579Gln. Heterozygosity for these mutations has been shown to impair cholesterol efflux by 40% to 85%. 11, [17] [18] [19] [20] Fourteen of the 36 ABCA1 mutation carriers were on statin therapy, including 3 homozygous subjects. All statin users had been on statin therapy for ≥2 years. Statin therapy was initiated by the patients treating physicians based on the current guidelines.
Twenty-one controls from the general population were matched for age and sex to carriers. Statin users were excluded from the control cohort (Table) . Total cholesterol levels were significantly lower in ABCA1 mutation carriers (P=0.005), largely because of 50% reduction in HDL-C (P<0.001). Apolipoprotein AI was decreased by 40% (P<0.001). Carriers on statins displayed a significantly lower low-density lipoprotein cholesterol level (P=0.009). Other parameters were not significantly different (Table) . Normalized wall index and mean wall thickness of the carotid arteries as determined by 3.0 Tesla MRI were increased in both statin using heterozygous ABCA1 mutation carriers (P<0.001 and P=0.006, respectively), as well as nonstatin using heterozygous ABCA1 mutation carriers (P<0.001 and P=0.002, respectively; Figure  I in the online-only Data Supplement), consistent with earlier reports. 11 18 F-FDG PET/CT ( 18 F-FDG PET/CT) scanning was performed in a random subset of heterozygous ABCA1 mutation carriers (n=14) and controls (n=15). In the whole group, the target: background ratio (TBR) was not significantly different in heterozygous ABCA1 mutation carriers than in controls (data not shown). However, the average mean TBR of the left and right carotid was 20% higher in nonstatin using heterozygous ABCA1 mutation carriers than in statin using heterozygous ABCA1 mutation carriers (P=0.03 for left mean TBR; P=0.006 for right mean TBR; Figure 1 ). After excluding the heterozygous ABCA1 mutation carriers using statins, the mean TBR in the left and right carotid was higher in heterozygous ABCA1 mutation carriers than in controls (P=0.06 and 0.02, respectively; Figure 1 ). Maxmium TBR was significantly higher for the right carotid (P=0.008; Figure 1 ) and showed a trend to an increase in the left carotid (P=0.06). In Figure  II in the online-only Data Supplement, representative images of CT and 18 F-FDG PET/CT right carotid arteries of heterozygous ABCA1 mutation carriers, controls, and heterozygous ABCA1 mutation carriers using statins are displayed.
Vascular 18 F-FDG PET/CT
Because the TBR signal depends on glucose uptake in macrophages in the arterial wall 21 and ABCA1 has been reported to have a role in glucose uptake, 22 we evaluated a potential direct effect of ABCA1 expression on macrophage glucose uptake. Macrophage-glucose uptake did not differ between heterozygous ABCA1 mutation carriers and controls ( Figure  III in the online-only Data Supplement), indicating that the differences in TBR signal cannot be explained by a direct effect of ABCA1 on glucose uptake.
Systemic Inflammatory Phenotype in ABCA1 Mutation Carriers
To assess whether the apparent inflammatory phenotype in the arterial wall of heterozygous ABCA1 mutation carriers also manifested itself systemically, plasma cytokines were measured in both heterozygous and homozygous ABCA1 mutation carriers. Plasma levels of tumor necrosis factor α (TNFα) were significantly higher in homozygous ABCA1 mutation carriers versus controls (Figure 2A ). In line with the PET/ CT data, TNFα levels were significantly higher in nonstatin using heterozygous ABCA1 mutation carriers than in statin using heterozygous carriers who had levels similar to controls ( Figure 2A ). TNFα levels also seemed to be higher in the nonstatin using homozygous carriers than in statin using homozygous carriers. Plasma levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) were increased in heterozygous ABCA1 mutation carriers and homozygous ABCA1 mutation carriers than in controls ( Figure 2B ). In contrast to TNFα, no effect of statin use was observed ( Figure 2B and 2C).
Inflammatory Gene Expression in Monocytes From Heterozygous ABCA1 Mutation Carriers
To assess whether monocytes showed increased inflammatory gene expression, we isolated CD14+ monocytes from heterozygous ABCA1 mutation carriers and controls and measured TNFα, IL-1β, MCP-1, and IL-6 mRNA expression. TNFα mRNA was increased in heterozygous ABCA1 mutation carriers than in controls (2.5-fold; P<0.01) ( Figure 3 ). Interestingly, statin use did not affect the increase in TNFα mRNA. Expression of IL-1β, MCP1, and IL-6 was not different from controls ( Figure 3 ).
ABCA1 Deficiency and Macrophage Inflammation
To examine whether knockdown of ABCA1 in human macrophages resulted in increased expression of inflammatory genes, we used siRNA to knock-down ABCA1 in human THP-1 macrophages. This resulted in a 64% decrease in ABCA1 mRNA expression and a 23% increase in ABCG1 mRNA expression ( Figure IVA and IVB in the online-only Data Supplement). ABCA1 protein was also decreased by ≈50% ( Figure IVA and IVB in the online-only Data Supplement). There were marked increases in the expression of IL-1β and inducible nitric oxide synthase mRNA, a small increase in IL-6 mRNA and no change in TNFα mRNA ( Figure 4 ). Addition of a cholesterol-poor reconstituted HDL preparation resulted in decreased IL-1β, inducible nitric oxide synthase, and TNFα mRNA expression, whereas IL-6 expression was relatively unchanged (Figure 4 ), likely reflecting cholesterol efflux via non-ABCA1-dependent pathways, such as ABCG1.
Proinflammatory Effects of Apolipoprotein B-Depleted Plasma and Lipoprotein-Deficient Plasma From ABCA1-Deficient Subjects
To determine whether the increased plasma inflammatory cytokines and decreased HDL from ABCA1 mutation carriers could contribute to enhanced macrophage inflammation, we added polyethylene glycol supernatant (apolipoprotein B-depleted plasma still containing HDL) from controls, heterozygous, and homozygous ABCA1 mutation carriers to THP-1 macrophages. Only the apolipoprotein B-depleted plasma from homozygous ABCA1 mutation carriers increased mRNA expression of inflammatory cytokines ( Figure 5A ). This could reflect the virtual absence of HDL in the plasma from homozygous subjects, whereas the half normal levels of HDL in the heterozygous subjects may have been sufficient to suppress inflammatory cytokine production. To test this idea further, we added pooled lipoprotein-deficient serum from controls, heterozygous, and homozygous ABCA1 mutation carriers to THP-1 macrophages. Lipoprotein-deficient serum from heterozygous ABCA1 mutation carriers increased TNFα, IL-1β, and MCP-1 mRNA expression, whereas lipoproteindeficient serum from homozygous ABCA1 mutation carriers caused a more marked an widespread increase in mRNA Values are indicated as mean±SD unless otherwise indicated. P value for student t test, than in control, unless otherwise specified. P value 1 tests ABCA1 mutation carriers vs controls; P value 2 tests ABCA1 mutation carriers not on statins vs ABCA1 mutation carriers on statins. HDL indicates high-density lipoprotein; Het, heterozygous subjects; Hom, homozygous subjects; LDL, low-density lipoprotein; MWT, mean wall thickness; N.a., not applicable; Tot, total; and NWI, normalized wall index. *Parameters tested by means of χ 2 test. †Parameters for which median and interquartile range are given and testing was performed by Mann-Whitney U test.
expression of inflammatory cytokines (TNFα, IL-1β, MCP-1, IL-8, and inducible nitric oxide synthase) ( Figure 5B) . These experiments suggest that in ABCA1 mutation carriers half normal HDL levels may be sufficient to counteract the effect of proinflammatory cytokines in plasma, whereas in homozygous subjects the near absence of HDL is permissive for the proinflammatory effect. Thus, in heterozygotes, partial ABCA1 deficiency (comparable with the partial knockdown in Figure 4 ) in monocytes and macrophages may make a key contribution to inflammatory cytokine expression.
Discussion
ABCA1 mutation carriers displayed both increased vessel wall inflammation as assessed by 18 F-FDG PET/CT and increased systemic inflammation as reflected by a proinflammatory plasma cytokine profile and increased inflammatory gene expression in circulating monocytes. In vitro experiments with human THP-1 macrophages revealed a proinflammatory effect of lipoprotein-deficient serum from heterozygous and homozygous ABCA1 mutation carriers, most likely secondary to increased levels of plasma cytokines, as well as a cell intrinsic effect of ABCA1 deficiency. Both cellular ABCA1 deficiency and reduced levels of plasma HDL may contribute to increased monocyte and macrophage inflammatory responses; however, our findings suggest that in heterozygotes cellular ABCA1 deficiency may have the predominant role, whereas in homozygous subjects, both cellular ABCA1 deficiency and the absence of plasma HDL may also contribute. Our findings are consistent with studies in mouse macrophages, in which genetic deficiency of Abca1 leads to enhanced inflammatory gene expression. [13] [14] [15] [16] This has been attributed to increased plasma membrane lipid raft formation promoting signaling via toll-like receptors 2, 3, and 4. [14] [15] [16] 23 Our data show an association between ABCA1 deficiency and increased systemic and plaque inflammation in humans, probably contributing to the increased atherosclerotic plaque volume that has been observed in ABCA1 mutation carriers. 10,11 18 F-FDG PET/CT has emerged as a reliable noninvasive technique for visualization of metabolic activity in the arterial wall in humans. 24 Metabolic activity likely reflects the inflammatory state of the arterial wall because the arterial uptake of 18 F-FDG has been shown to correlate with circulating inflammatory biomarkers, 25 inflammatory gene expression, 26 cardiovascular disease risk factors, 27 and the number of plaque macrophages. 28 We showed that the 18 F-FDG uptake in the arterial wall of nonstatin using heterozygous ABCA1 mutation carriers was increased than in matched controls, paralleling an increase in vessel wall thickness. Although suspected based on studies in macrophages from Abca1 -/mice, [13] [14] [15] [16] this is the first confirmation of an in vivo role for ABCA1 in the suppression of inflammation in humans. The finding of increased vessel wall inflammation in heterozygous ABCA1 mutation carriers is likely to contribute to their increased cardiovascular risk 8, 9 because carotid arterial wall 18 F-FDG uptake has been associated with increased cardiovascular risk, independent of the degree of stenosis. 29, 30 Interestingly, the increased inflammatory status in the vessel wall of heterozygous ABCA1 mutation carriers was manifested systemically because plasma levels of TNFα, MCP-1, and IL-6 were also increased. This is consistent with previous reports, showing that ABCA1 suppresses secretion of IL-1β, IL-6, and TNFα. 15, 16, 31, 32 Furthermore, TNFα mRNA expression was increased in circulating monocytes, consistent with a systemic proinflammatory state. These findings are also consistent with reports that plasma C-reactive protein levels are negatively Proinflammatory cytokines in plasma of controls, heterozygous (het), and homozygous (hom) ABCA1 mutation carriers. Plasma was isolated from controls, heterozygous ABCA1 mutation carriers not using (ABCA1 het) or using a statin (ABCA1 het statin), and homozygous ABCA1 mutation carriers not using (ABCA1 hom) or using a statin (ABCA1 hom statin). Levels of proinflammatory cytokines were assessed using ELISA. A, Tumor necrosis factor α (TNFα), (B) monocyte chemoattractant protein-1 (MCP-1), and (C) interleukin-6 (IL-6). In all graphs, each datapoint represents 1 patient or control. The mean is indicated. *P<0.05, **P<0.01, and ***P<0.001. associated with ABCA1 mRNA levels in human peripheral monocytes. 33 The cross-sectional design of this study precludes us from answering whether plaque inflammation is causal or secondary to atherosclerosis. However, because the increases in inflammatory mediators in our study are secondary to genetic changes in ABCA1, and knockdown of ABCA1 increases inflammatory gene expression, it is reasonable to conclude that excessive plaque inflammation contributes to increased atherosclerotic burden. 14, 23 Our findings suggest an anti-inflammatory effect of statin treatment in humans as determined by both reduced 18 F-FDG uptake in the arterial wall and decreased circulating levels of cytokines. Although the effect of statins on 18 F-FDG PET/CT signal in atherosclerotic subjects is in line with previous publications, [34] [35] [36] the ≈20% decrease in TBR in statin users in our study is larger than the ≈10% 34 and ≈9% 36 decreases in other reports. This may be explained by the short treatment period of 3 to 6 months in these intervention trials versus long-term use in our patients or the increased inflammatory status of ABCA1 mutation carriers. The finding of a statin effect on 18 F-FDG PET/CT, but not on MRI, underlines the capacity of 18 F-FDG PET/CT to visualize inflammation. Folco et al 21 have suggested a specific effect of statins to decrease the uptake of 18 F-FDG-glucose by macrophages in a hypoxic plaque environment; a contribution of such an effect to our results cannot be excluded.
Interestingly, among the inflammatory cytokines measured, TNFα mRNA levels were clearly increased in monocytes of ABCA1 heterozygotes and TNFα protein levels were increased in plasma; however, statins lowered TNFα plasma levels while appearing not to affect monocyte TNFα mRNA levels. TNFα is an important inflammatory cytokine that has Figure 3 . Inflammatory cytokine expression in monocytes from controls and heterozygous ABCA1 mutation carriers. Peripheral blood mononuclear cells (PBMCs) were isolated from heterozygous ABCA1 mutation carriers or controls (n=6 per group). CD14+ monocytes were isolated from PBMCs using magnetic beads and mRNA expression for tumor necrosis factor α (TNFα), interleukin-1β (IL-1β), monocyte chemoattractant protein-1 (MCP-1), and interleukin-6 (IL-6) was assessed and corrected for the housekeeping gene cyclophilin. Data are presented as mean±SEM. **P<0.01. proatherogenic effects especially on the endothelium and smooth muscle cells. TNFα is synthesized as a type 2 membrane protein and released from cells as result of the activity of ADAM17 (tumor necrosis factor-α-converting enzyme). 37 This raises the intriguing possibility of an independent effect of statins on TNF processing.
In conclusion, our data demonstrate a proinflammatory state in heterozygous and homozygous ABCA1 mutation carriers as reflected by increased circulating cytokines. This is attributed to a cellular effect of ABCA1 deficiency with an additional contribution of lower HDL levels especially in homozygous subjects. Our findings suggest that the increased inflammation documented in ABCA1-deficient cells and animal models [14] [15] [16] 23 is also present in humans. The increased inflammation in ABCA1 mutation carriers, documented by an increased carotid 18 F-FDG PET/CT signal, seems to be attenuated by statins, as shown by normalization of 18 F-FDG PET/CT and plasma cytokine levels.
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